CytomX Therapeutics, Inc. is working with Regeneron Pharmaceuticals, Inc. to identify and validate conditionally activated bispecific cancer therapies by combining their respective platform technologies in a deal that could be worth more than $2bn.
The San Francisco, CA-based biotech is set to receive an upfront payment of $30m and will be eligible for milestone payments of up to $2bn plus tiered royalties on potential product sales